Table 3.
General characteristics of mRNA-based vaccines for COVID-19.
| BNT162b2 | mRNA-1273 | |
|---|---|---|
| Efficacy | 95% | 94.1% |
| Technology | mRNA | mRNA |
| Required doses | 2 | 2 |
| Days between doses | 21 | 1 month |
| Recommended age group as per US FDA | 12 years of age and older (purple cap, gray cap), 5–11 years of age (orange cap) |
18 years and older |
| Common adverse reactions | acute anaphylactic reaction, myocarditis and pericarditis, fainting, fatigue, headache, muscle pain, chills, joint pain, swelling at the injection site, fever, redness at the injection site | acute allergic reactions, myocarditis and pericarditis, syncope, pain at the injection site, fatigue, headache, myalgia, arthralgia, chills, nausea/vomiting, axillary swelling/tenderness, fever, erythema at the injection site, and rash |
| Storage temperature | −80 to −60 °C | −25 °C to −15 °C |
| Duration of stability at fridge temperature | 5 days | 30 days |